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Second, the authors excluded patients
with advanced breast cancer because ofthe
significant mortality in this group.
Third, the authors argued that exdusion
ofwomen with specific exposures is unlikely
to have introducedbias. However, weare not
told how many of the original study group
were successfully contacted, what proportion
had died, and what proportion of those
recontacted, and eligible, agreed to partici-
pate in the second study. Did these propor-
tions differbetween cases and controls?
Fourth, in addition to the possibility of
selection bias due to differential recruitment
in the second study, the lack ofa significant
difference between cases and controls may
be due to the restriction of the study to
early stage cancer. In the study by Kabat et
al. (2), among postmenopausal women the
ratio of2-OHE1/16a-OHE1 was strongly
and inversely associated with breast cancer.
However, this association was driven pri-
marily by a strong association with later
stage cancer (stages III and IV).
Finally, in the small sample forwhich the
results were reported, adjustment for breast
cancerriskfactors (indudingageatmenarche,
age atfirst pregnancy, parity, familyhistoryof
breast cancer, and ethnicity) was apparently
not carried out. This is critical because the
matched-pair design ofthe original studywas
notmaintained in thecurrentstudy.
We look forward to the full report,
which will hopefully provide more detailed
information on these questions. It should be
clearly understood that these results, as they
now stand, are in no way inconsistent with
our hypothesis that the metabolite ratio is a
valid biochemical marker forbreast cancer.
H. Leon Bradlow
Strang Cancer Research Laboratory
NewYork, NewYork
Geoffery C. Kabat
Department ofPreventive Medicine
University Medical Center
State University ofNewYork
at Stony Brook
StonyBrook, NewYork
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Response
Our pilot study (1) did not confirm
Bradlow et al.'s hypothesis of an inverse
association between the urinary ratio 2-
OHE1l16a-OHE1 and breast cancer risk.
Kabat and Bradlow raise a number ofissues
that they believe might pose problems in
ourstudy. We examine them in the order in
which theywere raised.
Bradlowand Kabat note thatweexcluded
approximately 55-60% ofparticipants in the
original study. As we explicitly state in our
description ofourpilot study (1), we contact-
edwomenwhohadparticipated in aprevious
case-control study at our institution. For the
current study, we only contacted women
with early stage (< stage II) cancers. This was
out ofconcern that the levels of the urinary
metabolites might be altered by the disease in
later stage patients and that any association
would be the result ofthe disease rather than
the cause of it. We also had a number of
exclusion criteria that applied both to cases
and to controls. We excluded cases and con-
trols who were current smokers, who were
obese, or who had recently used chemothera-
py, had anesthesia, orhad used other medica-
tions that could interfere with estrogen
metabolism. We agree that this might limit
the generalizability of the findings, but it
should not result in selection bias because the
criteriawereapplied equally to both cases and
controls. These restrictions were essential
because of concern that these factors could
influence urinary metabolite levels and thus
produce a noncausal association between the
ratio of2-OHEI to 16a-OHE1 anddisease.
In our pilot study publication, we pro-
vided the data for the first 25 cases and 23
controls we studied. We did not provide the
participation rates/exclusion rates in each
group at that time since the data collection
was ongoing, so thesample in ourpilotstudy
should be regarded as a convenience sample.
Further information will be provided in the
full study, whichwill becompletedshortly.
Kabat et al. (2) provided no information
onchoice ofcases andcontrols. In theirstudy,
cases were 4 times as likely as controls to cur-
rently use alcohol and 3.8 times as likely to
have a chronic condition (such as hyperten-
sion, arthritis, diabetes, asthma, glaucoma,
heart disease ,and allergies); these large differ-
encessuggest that theircontrol group may not
havebeen anappropriate comparison group.
Bradlow and Kabat are concerned that
lack of adjustment for various breast cancer
risk factors would have biased our results
toward the null. Although this is possible,
their interpretation oftheir own results makes
it appear unlikely. They reported that the 2-
OHE1/16a-OHEI ratio "did not show any
consistent associations with age, race/ethnici-
ty, age at first birth, parity, body mass index,
family history of breast cancer, smoking or
alcohol intake" (2). Bradlow and Kabat give
no discussion ofwhy the confounding would
be negative. Indeed, positive confounding
would appear to be equally, and possibly
more, likely. In reality, it should be remem-
bered that most ofthe breast cancer risk fac-
tors are relatively weak and their association
with urinary metabolites would need to be
ratherstrongto influence theassociationssub-
stantively. We will evaluate all these factors as
potential confounders in ourfullstudy.
Our results are, in fact, in agreement
with those reported by Kabat et al. (2), who
also found no association between the ratio
ofurinary 2-OHE1 to 16a-OHE1 and early
stage breast cancer. As they indicate in their
letter, the association they found overall was
driven primarily by strong associations with
later stage cancer in postmenopausal
women (the same association was not found
for premenopausal women). The strong
association Kabat et al. (2) report in post-
menopausal women with advanced disease
may simply be an artifact of subgroup
analysis, a result ofthe disease process itself,
or the treatment their cases obtained. While
it would be useful ifthey attempted to eval-
uate whether treatment or some other
confounder might explain their result, in
reality, it is difficult to be certain that it did
not. For this reason, we excluded women
with advanced disease from our study.
The 2-OHE1 and 16a-OHE1 assays
reported in our studywere conducted in the
laboratory ofBradlow and colleagues at the
Strang Cornell Research Laboratory, and we
are indebted to him for this and for other
help he gave in the execution ofthe study.
Giske Ursin
Stephanie London
Malcolm C. Pike
USC/Norris Comprehensive
Cancer Center
University ofSouthern California
Los Angeles, California
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